Sep 2026· i Medicina· Vol 7 9, pp.
101268
· 0 citations· 10 references
Medicine
TL;DR
The treatment of PDAC is transitioning from uniform cytotoxic chemotherapy toward precision strategies guided by molecular identity and disease stage, and seven trials addressing these dimensions may collectively redefine PDAC treatment.
Abstract
The treatment of PDAC is transitioning from uniform cytotoxic chemotherapy toward precision strategies guided by molecular identity and disease stage. RAS and PARP inhibitors and personalized neoantigen vaccination have created new options across metastatic and resectable disease. Chemotherapy timing relative to surgery and post-resection surveillance represent other important axes of precision oncology. Seven trials addressing these dimensions may collectively redefine PDAC treatment.
Neoadjuvant therapy for pancreatic adenocarcinoma (PDAC) has evolved from single‐agent to multi‐agent approaches, largely informed by metastatic disease studies demonstrating improved survival; albeit at the price of increased toxicity. It remains unclear how response to varied neoadjuvant regimens impact survival. We...
M. Suraju, Brian C. Longbottom, Jasmine Peterson et al.· Journal of Surgical Oncology· 0 citations
The management of endometrial cancer has evolved with the integration of molecular
classification, minimally invasive surgery, sentinel lymph node mapping, and immune checkpoint
inhibitors. These advances have improved risk stratification and expanded treatment options across early-
stage and advanced disease.
Fidan Seyfullayeva· MedEpicent:Journal of Medica...· 0 citations
The objective of this study is to explore and validate a novel prognostic index for patients with locally advanced or metastatic biliary tract cancer (BTC) treated with first‐line therapy with cisplatin, gemcitabine, and durvalumab.
M. Persano, A. Casadei-Gardini, L. Fornaro et al.· Cancer· 0 citations
Advances in technology have allowed for the characterization of tumors at the genomic, transcriptomic, and proteomic levels. There are well-established targets for biliary tract cancers, with exciting new targets emerging in pancreatic ductal adenocarcinoma and potential targets in hepatocellular carcinoma. Taken toget...
T. Newhook, Susan Tsai, F. Meric-Bernstam· Hematology/Oncology Clinics...· 0 citations
Adding a third drug to standard immunotherapy combinations can prolong disease control but has not yet improved survival benefit and, when used empirically, increases toxicity. The priority now is validated biomarkers for patient selection and mechanistically distinct therapies, rather than more unselected triplets.
J. Molina-Cerrillo, V. G. dos Santos, T. Alonso-Gordoa· European Urology Oncology· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.
